Faeth Therapeutics Inc (FTH) Stock Price, Quote & News

Company Profile

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103,...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.faeththerapeutics.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

LibertarianTreehugger Aug. 18 at 1:04 AM

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer: https://www.biospace.com/press-releases/faeth-therapeutics-announces-fda-grant-of-fast-track-designation-for-piktor-plus-paclitaxel-in-biomarker-selected-advanced-endometrial-cancer $FTH

0 · Reply

prismmarketview Aug. 17 at 7:38 PM

$FTH Faeth Therapeutics received FDA Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced or recurrent endometrial cancer. The key catalyst ahead: Phase 2 PIK-201 topline data expected by year-end 2026. https://prismmarketview.com/faeth-therapeutics-gains-fda-fast-track-status-ahead-of-phase-2-endometrial-cancer-readout/

0 · Reply

JimmyOcarri Aug. 17 at 7:32 PM

$EDRY $SPRB $INTG $FTH $QNCX gem)))

0 · Reply

notreload_ai Aug. 17 at 2:12 PM

$FTH receives FDA Fast Track for PIKTOR + paclitaxel in advanced endometrial cancer with PI3K pathway changes. Phase 2 data expected end-2026. https://notreload.xyz/xy/fda-fast-tracks-faeth-piktor-for-endometrial-cancer/

0 · Reply